Compare Marsh & McLennan Companies, Inc. (MRSH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Novavax Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.27B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 69.7× Novavax Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MRSH | NVAX | |
|---|---|---|
Market Cap | $91.27B | $1.31B |
Sector | Financials | Health |
52-Week High | $211.21 | $11.19 |
52-Week Low | $157.32 | $6.22 |
Enterprise Value | $111.95B | $889.30M |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.
The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
